drugset / Trial / NCT02728388

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

NCT02728388

Phase 2 Terminated 30 enrolled Donald Basel
NaSingle-groupOpen-labelTreatment

Summary

The investigators wish to determine the time to disease progression for benign neurofibromas treated with Levulan Kerastick topical photosensitizer and red light photodynamic therapy (PDT) in patients with neurofibromatosis type 1 (NF1). The investigators also wish to measure tumor size for control and treatment tumors in order to gain insights into tumor growth rates.

Timeline

Start
2016-09-16
Primary completion
2025-12-31
Completion
2026-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Aminolevulinic Acid Diagnostic / imaging agent Topical